11099 North Torrey Pines Road
Genea Biocells developed the world’s largest and most varied bank of ethically derived, NIH approved human embryonic stem cells and offers the world's first scalable, high-yield differentiation protocol for skeletal muscle cells for modeling muscular dystrophies and neuromuscular disorders. We commercialize our technologies via product sales (cells, media, small molecules) and research services, including targeted chemistry and screening, assay development, customized cell supply and culture process optimization for clinical discovery and translation using the latest high-content screening capabilities and robotics.
Genea Biocells also focuses on therapeutics discovery research for neuromuscular diseases using proprietary human pluripotent stem cell technologies. Our lead programs are (1) small molecule modulators of FSH muscular dystrophy, one of the most common genetic muscle disorders, and (2) stem cell-derived satellite cells for cell therapy.
The company operates from Sydney, Australia and recently expanded into San Diego, CA. Genea Biocells is part of the Genea Group (formerly Sydney IVF Limited), a private, unlisted company that has been operating world leading IVF clinics since 1985.